165 related articles for article (PubMed ID: 34876409)
1. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
Friedman CF; Hainsworth JD; Kurzrock R; Spigel DR; Burris HA; Sweeney CJ; Meric-Bernstam F; Wang Y; Levy J; Grindheim J; Shames DS; Schulze K; Patel A; Swanton C
Cancer Discov; 2022 Mar; 12(3):654-669. PubMed ID: 34876409
[TBL] [Abstract][Full Text] [Related]
2. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
Lee KW; Van Cutsem E; Bang YJ; Fuchs CS; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Chao J; Wainberg ZA; Cao ZA; Aurora-Garg D; Kobie J; Cristescu R; Bhagia P; Shah S; Tabernero J; Shitara K; Wyrwicz L
Clin Cancer Res; 2022 Aug; 28(16):3489-3498. PubMed ID: 35657979
[TBL] [Abstract][Full Text] [Related]
3. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
4. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
[TBL] [Abstract][Full Text] [Related]
5. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
[TBL] [Abstract][Full Text] [Related]
6. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
[TBL] [Abstract][Full Text] [Related]
7. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
[TBL] [Abstract][Full Text] [Related]
8. Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers.
Mo SF; Cai ZZ; Kuai WH; Li X; Chen YT
Front Cell Dev Biol; 2023; 11():1209243. PubMed ID: 37305681
[No Abstract] [Full Text] [Related]
9. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
Kurzrock R; Bowles DW; Kang H; Meric-Bernstam F; Hainsworth J; Spigel DR; Bose R; Burris H; Sweeney CJ; Beattie MS; Blotner S; Schulze K; Cuchelkar V; Swanton C
Ann Oncol; 2020 Mar; 31(3):412-421. PubMed ID: 32067683
[TBL] [Abstract][Full Text] [Related]
10. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
He J; Kalinava N; Doshi P; Pavlick DC; Albacker LA; Ebot EM; Tukachinsky H; Pratt J; Fusaro G; Oxnard GR; Green G; Fabrizio D; Baden J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38035725
[TBL] [Abstract][Full Text] [Related]
12. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors.
Shao C; Li G; Huang L; Pruitt S; Castellanos E; Frampton G; Carson KR; Snow T; Singal G; Fabrizio D; Alexander BM; Jin F; Zhou W
JAMA Netw Open; 2020 Oct; 3(10):e2025109. PubMed ID: 33119110
[TBL] [Abstract][Full Text] [Related]
14. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
15. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
16. Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
Dupain C; Gutman T; Girard E; Kamoun C; Marret G; Castel-Ajgal Z; Sablin MP; Neuzillet C; Borcoman E; Hescot S; Callens C; Trabelsi-Grati O; Melaabi S; Vibert R; Antonio S; Franck C; Galut M; Guillou I; Halladjian M; Allory Y; Cyrta J; Romejon J; Frouin E; Stoppa-Lyonnet D; Wong J; Le Tourneau C; Bièche I; Servant N; Kamal M; Masliah-Planchon J
BMC Biol; 2024 Feb; 22(1):43. PubMed ID: 38378561
[TBL] [Abstract][Full Text] [Related]
17. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity.
Karamitopoulou E; Andreou A; Wenning AS; Gloor B; Perren A
Eur J Cancer; 2022 Jul; 169():64-73. PubMed ID: 35512587
[TBL] [Abstract][Full Text] [Related]
18. Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
Yan H; Song L; Li Y; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Huang Z; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zhang Y; Zeng L
Cancer Immunol Immunother; 2024 Mar; 73(4):74. PubMed ID: 38451314
[TBL] [Abstract][Full Text] [Related]
19. Are You a TMBeliever? Mutations and Atezolizumab Response in Solid Tumors.
Maron SB; Klempner SJ
Cancer Discov; 2022 Mar; 12(3):602-603. PubMed ID: 35257152
[TBL] [Abstract][Full Text] [Related]
20. [Crosstalk of Cancer Genomic Test and Cancer Immune Therapy].
Nishihara H
Gan To Kagaku Ryoho; 2022 Mar; 49(3):248-254. PubMed ID: 35299175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
